Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Mr Helmut Drexler
There are millions of new cancers every year and 60% of patients receive chemotherapy and therefore are at risk of chemotherapy-induced cardiotoxicity. In fact, it appears that chemotherapy in childhood increases cardiac risk 8 fold. Chemotherapy-induced cardiomyopathy has a bad prognosis. It is crucial to identify these patients early. If treatment with ACE inhibitors and ß-blockers are instituted later than 6 months after LV dysfunction and heart failure occurs, there is no beneficial effect any more.
Ongoing damage can be identifed by troponin T or I measurement, in fact prolonged elevated levels of troponin predicted LV dysfunction.
Cachexia is a major complicating condition and impairs outcome both in patients with cancer and heart failure. It appears that development of cachexia can be attenuated with ACE-inhibitors and ß-blockers. Spironolactone may even be able to increase body weight in this setting.
Early identification of cardiotoxicity after chemotherapy is crucial and early initiation of treatment with ACE inhibitors and ß-blockers is quite effective.
Heart failure and cancer
© 2017 European Society of Cardiology. All rights reserved